Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sucampo Pharmaceuticals, Inc. : Sucampo to be Added to the NASDAQ Biotechnology Index

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2013 | 12:45pm CEST

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that NASDAQ OMX Group, Inc. (NASDAQ: NDAQ) will include the company in the NASDAQ Biotechnology Index® (NASDAQ: NBI) effective prior to market open on Monday, May 20, 2013.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization weighted index. Among the various criteria that must be met in order to be eligible for inclusion in this index are a market capitalization of at least $200 million and an average daily trading volume of at least 100,000 shares. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com.

AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG.

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUCAMPO PHARMACEUTICALS, I
08/11 SUCAMPO PHARMACEUTICALS : Study Results Published in The Lancet Demonstrate Safe..
08/07 SUCAMPO PHARMACEUTICALS : Drug Makers Stock Performance Review -- DURECT, Sucamp..
08/02 SUCAMPO PHARMACEUTICALS : reports 2Q loss
08/02 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/02 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
08/02 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Results of Operations ..
08/02 Sucampo Reports Second Quarter 2017 Financial Results
08/02 SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
07/19 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Departure of Directors..
07/19 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
More news
News from SeekingAlpha
08/02 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2017 Results - Earn..
08/02 Sucampo Pharma Q2 revenues up 15%; non-GAAP EPS up 17%; reiterates guidance
08/02 Sucampo beats by $0.01, beats on revenue
07/27 SUCAMPO : A Shift Toward Rare Diseases
05/23 Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017..
Financials ($)
Sales 2017 235 M
EBIT 2017 99,4 M
Net income 2017 -91,5 M
Debt 2017 243 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 11,02
EV / Sales 2017 3,07x
EV / Sales 2018 2,49x
Capitalization 477 M
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,7 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.-25.83%477
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS26.41%50 145
VERTEX PHARMACEUTICALS101.07%37 346